Omnicell Reports Strong Q4 2025 Earnings and Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 06 2026
0mins
Source: seekingalpha
- Strong Financial Performance: Omnicell reported total revenue of $314 million for Q4 2025, reflecting a 2% increase from Q4 2024, indicating sustained demand and solid execution in the medication management sector.
- Annual Recurring Revenue Growth: The company exited 2025 with an annual recurring revenue (ARR) of $636 million, a 10% increase year-over-year, showcasing strong customer demand for new products, particularly Titan XT and the OmniSphere platform.
- Optimistic Outlook: Management expects total revenue for Q1 2026 to be between $300 million and $310 million, with full-year revenue projected at $1.215 billion to $1.255 billion, demonstrating confidence in future market conditions.
- Enhanced Market Competitiveness: The successful launch of Titan XT and positive market feedback are expected to drive market share growth in medication management, especially with a replacement cycle opportunity exceeding $2.5 billion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OMCL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OMCL
Wall Street analysts forecast OMCL stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 44.360
Low
46.00
Averages
54.20
High
63.00
Current: 44.360
Low
46.00
Averages
54.20
High
63.00
About OMCL
Omnicell, Inc. is a healthcare technology provider focused on autonomous medication management, by unifying automation and AI-enabled intelligence, optimized by expert services, to drive clinical and business outcomes that are helping to improve efficiency and enhance patient safety for healthcare facilities. The Company is focused on helping its customers define and deliver a medication management strategy designed for pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. It provides a range of points of care medication and supplies dispensing systems, including automated systems and offers advanced automation solutions, including robotics designed to automate work, streamline workflows, and reduce human error. It provides central pharmacy automation solutions for both medication dispensing and IV compounding and provides patient engagement solutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Small-Cap Stocks Set for Best Performance in 30 Years
- Strong Small-Cap Performance: Small-cap stocks are on track for their best performance in over 30 years, with the Russell 2000 index reaching 3,033.75, up 21% in 2026, indicating robust market momentum and the potential for the best first half since 1991.
- Investment Recommendations: Bank of America and TD Cowen have recommended several small-cap stocks, including Freshpet and Omnicell, suggesting these companies in healthcare technology, retail, and biotech are well-positioned for growth, making them attractive for investors looking to capitalize on market opportunities.
- Freshpet's Growth Potential: With only a 2.7% share of the pet food market, Freshpet is expected to benefit from the 'pet humanization' trend, and TD Cowen has a buy rating with an $80 price target, indicating about 50% upside potential.
- Omnicell's Product Innovation: Omnicell is set to exceed expectations with new pharmacy automation products like Titan XT and OmniSphere, and Bank of America has a buy rating with a $70 price target, suggesting a 77% upside potential.
See More
Omnicell Appoints Dan Mandoli as Senior VP and General Manager
- Executive Appointment: Omnicell has appointed Dan Mandoli as Senior Vice President and General Manager of Specialty Pharmacy Services, leveraging over 30 years of experience in pharmacy operations and specialty pharmacy services to enhance clinical and operational outcomes for the company.
- Growth Driver: Mandoli's extensive background in driving growth in specialty pharmacy operations for Fortune 50 and private equity-backed healthcare companies is expected to significantly support the expansion of Omnicell's 340B and specialty pharmacy businesses.
- Strategic Execution: Previously serving as COO at Altruix, Mandoli successfully led operational improvements across specialty pharmacy functions, showcasing his strategic execution capabilities in integrating acquisitions and building infrastructure for growth.
- Educational Engagement: Mandoli holds a Bachelor of Science degree from the University of Michigan and is actively involved in expanding educational access for first-generation college students, reflecting his commitment to social responsibility.
See More
Avory & Company Reduces Omnicell Holdings
- Share Reduction Transaction: On April 29, 2026, Avory & Company disclosed to the SEC that it sold 156,571 shares of Omnicell for approximately $6.55 million, indicating a diminished confidence in the company's future prospects.
- Decline in Holding Value: Following the sale, the value of Omnicell shares decreased by $8.01 million, reflecting not only the reduction in shares but also the impact of Omnicell's stock price fluctuations, with the current holding valued at $2.57 million.
- Portfolio Impact: Omnicell now represents only 3.33% of Avory & Company's reportable assets, while its top holding, VOO, accounts for 22.3%, suggesting a preference for other investments over Omnicell.
- Performance Analysis: Despite Omnicell reporting $310 million in revenue for Q1 2026, a 15% year-over-year increase, its stock has plummeted 68% since 2021, leading to investor caution regarding its long-term performance.
See More
Omnicell Reports Strong Q1 Earnings, Shares Surge Nearly 21%
- Significant Revenue Growth: Omnicell's Q1 revenue rose nearly 15% year-over-year to just under $310 million, surpassing analyst expectations of $304 million, indicating strong performance in the healthcare tech sector.
- Product and Service Gains: Product revenue increased by 20% to nearly $175 million, while service revenue grew by 8% to $135 million, reflecting robust demand for the company's core care solutions and connected device portfolio.
- Net Income Doubled: The company's non-GAAP net income more than doubled from $12 million to $25 million, with earnings per share at $0.55, significantly exceeding the market's expectation of $0.33, showcasing improved execution.
- Optimistic Future Guidance: Omnicell expects revenue for 2026 to range from $1.22 billion to $1.26 billion and has raised its non-GAAP earnings per share forecast to between $1.80 and $2.00, demonstrating confidence in future performance.
See More
Omnicell Exceeds Revenue and Profit Expectations in Q1
- Significant Revenue Growth: Omnicell's Q1 revenue rose nearly 15% year-over-year to just under $310 million, surpassing analyst expectations of $304 million, demonstrating strong performance in the healthcare technology sector.
- Profitability Improvement: The company's net income more than doubled from $12 million last year to $25 million, with non-GAAP earnings per share reaching $0.55, significantly exceeding the market's forecast of $0.33, reflecting enhanced business execution.
- Optimistic Guidance: Omnicell expects revenue for 2026 to be between $1.22 billion and $1.26 billion, while raising its non-GAAP earnings per share forecast to $1.80 to $2.00, showcasing management's confidence in future growth.
- Positive Market Reaction: Following the earnings release, the stock surged nearly 21% in a single day, indicating strong investor enthusiasm for Omnicell's robust performance and a positive outlook for its future development.
See More
Omnicell Q1 2026 Earnings Call Highlights
- Strong Financial Performance: Omnicell reported total revenue of $310 million in Q1 2026, reflecting a 15% year-over-year growth, demonstrating the company's robust execution in the medical device sector, which drives sustained revenue growth and market share expansion.
- Product and Service Revenue Growth: Product revenue reached $175 million, up 20% year-over-year, while service revenue was $135 million, increasing by 8%, indicating the company's successful response to product mix and customer demand, enhancing future profitability.
- Optimistic 2026 Outlook: The company maintains its full-year revenue guidance between $1.215 billion and $1.255 billion, while raising expectations for non-GAAP EBITDA and earnings per share, reflecting management's confidence in future growth and positive market demand.
- Titan XT Commercialization Progress: The Titan XT hardware is expected to begin shipping in the second half of 2026, alongside a phased rollout of OmniSphere functionality, marking a strategic positioning in new product development and market competition aimed at enhancing long-term revenue potential.
See More
Small-Cap Stocks Set for Best Performance in 30 Years
- Strong Small-Cap Performance: Small-cap stocks are on track for their best performance in over 30 years, with the Russell 2000 index reaching 3,033.75, up 21% in 2026, indicating robust market momentum and the potential for the best first half since 1991.
- Investment Recommendations: Bank of America and TD Cowen have recommended several small-cap stocks, including Freshpet and Omnicell, suggesting these companies in healthcare technology, retail, and biotech are well-positioned for growth, making them attractive for investors looking to capitalize on market opportunities.
- Freshpet's Growth Potential: With only a 2.7% share of the pet food market, Freshpet is expected to benefit from the 'pet humanization' trend, and TD Cowen has a buy rating with an $80 price target, indicating about 50% upside potential.
- Omnicell's Product Innovation: Omnicell is set to exceed expectations with new pharmacy automation products like Titan XT and OmniSphere, and Bank of America has a buy rating with a $70 price target, suggesting a 77% upside potential.
See More
Omnicell Appoints Dan Mandoli as Senior VP and General Manager
- Executive Appointment: Omnicell has appointed Dan Mandoli as Senior Vice President and General Manager of Specialty Pharmacy Services, leveraging over 30 years of experience in pharmacy operations and specialty pharmacy services to enhance clinical and operational outcomes for the company.
- Growth Driver: Mandoli's extensive background in driving growth in specialty pharmacy operations for Fortune 50 and private equity-backed healthcare companies is expected to significantly support the expansion of Omnicell's 340B and specialty pharmacy businesses.
- Strategic Execution: Previously serving as COO at Altruix, Mandoli successfully led operational improvements across specialty pharmacy functions, showcasing his strategic execution capabilities in integrating acquisitions and building infrastructure for growth.
- Educational Engagement: Mandoli holds a Bachelor of Science degree from the University of Michigan and is actively involved in expanding educational access for first-generation college students, reflecting his commitment to social responsibility.
See More
Avory & Company Reduces Omnicell Holdings
- Share Reduction Transaction: On April 29, 2026, Avory & Company disclosed to the SEC that it sold 156,571 shares of Omnicell for approximately $6.55 million, indicating a diminished confidence in the company's future prospects.
- Decline in Holding Value: Following the sale, the value of Omnicell shares decreased by $8.01 million, reflecting not only the reduction in shares but also the impact of Omnicell's stock price fluctuations, with the current holding valued at $2.57 million.
- Portfolio Impact: Omnicell now represents only 3.33% of Avory & Company's reportable assets, while its top holding, VOO, accounts for 22.3%, suggesting a preference for other investments over Omnicell.
- Performance Analysis: Despite Omnicell reporting $310 million in revenue for Q1 2026, a 15% year-over-year increase, its stock has plummeted 68% since 2021, leading to investor caution regarding its long-term performance.
See More
Omnicell Reports Strong Q1 Earnings, Shares Surge Nearly 21%
- Significant Revenue Growth: Omnicell's Q1 revenue rose nearly 15% year-over-year to just under $310 million, surpassing analyst expectations of $304 million, indicating strong performance in the healthcare tech sector.
- Product and Service Gains: Product revenue increased by 20% to nearly $175 million, while service revenue grew by 8% to $135 million, reflecting robust demand for the company's core care solutions and connected device portfolio.
- Net Income Doubled: The company's non-GAAP net income more than doubled from $12 million to $25 million, with earnings per share at $0.55, significantly exceeding the market's expectation of $0.33, showcasing improved execution.
- Optimistic Future Guidance: Omnicell expects revenue for 2026 to range from $1.22 billion to $1.26 billion and has raised its non-GAAP earnings per share forecast to between $1.80 and $2.00, demonstrating confidence in future performance.
See More
Omnicell Exceeds Revenue and Profit Expectations in Q1
- Significant Revenue Growth: Omnicell's Q1 revenue rose nearly 15% year-over-year to just under $310 million, surpassing analyst expectations of $304 million, demonstrating strong performance in the healthcare technology sector.
- Profitability Improvement: The company's net income more than doubled from $12 million last year to $25 million, with non-GAAP earnings per share reaching $0.55, significantly exceeding the market's forecast of $0.33, reflecting enhanced business execution.
- Optimistic Guidance: Omnicell expects revenue for 2026 to be between $1.22 billion and $1.26 billion, while raising its non-GAAP earnings per share forecast to $1.80 to $2.00, showcasing management's confidence in future growth.
- Positive Market Reaction: Following the earnings release, the stock surged nearly 21% in a single day, indicating strong investor enthusiasm for Omnicell's robust performance and a positive outlook for its future development.
See More
Omnicell Q1 2026 Earnings Call Highlights
- Strong Financial Performance: Omnicell reported total revenue of $310 million in Q1 2026, reflecting a 15% year-over-year growth, demonstrating the company's robust execution in the medical device sector, which drives sustained revenue growth and market share expansion.
- Product and Service Revenue Growth: Product revenue reached $175 million, up 20% year-over-year, while service revenue was $135 million, increasing by 8%, indicating the company's successful response to product mix and customer demand, enhancing future profitability.
- Optimistic 2026 Outlook: The company maintains its full-year revenue guidance between $1.215 billion and $1.255 billion, while raising expectations for non-GAAP EBITDA and earnings per share, reflecting management's confidence in future growth and positive market demand.
- Titan XT Commercialization Progress: The Titan XT hardware is expected to begin shipping in the second half of 2026, alongside a phased rollout of OmniSphere functionality, marking a strategic positioning in new product development and market competition aimed at enhancing long-term revenue potential.
See More
